IRF1 and lung carcinoma: Given that prior studies have demonstrated that STAT1 controls anti-tumorigenic effects in part by upregulation of caspases, p21 and the IFN-regulated factor 1 (IRF1) pathway, we postulate that lung cancer cells may suppress TRIM14 to promote tumorigenicity through immune escape35, 36.